X0508 4 2025-12-29 0001635088 Roivant Sciences Ltd. ROIV 0001750050 Sukhatme Mayukh C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true true President & CIO false Common Shares 2025-12-29 4 M 0 748358 12.68 A 19584905 D Common Shares 2025-12-29 4 S 0 311873 21.74 D 19273032 D Common Shares 2025-12-29 4 J 0 436485 21.74 D 18836547 D Common Shares 2025-12-31 4 M 0 2449877 12.68 A 21286424 D Common Shares 2025-12-31 4 S 0 1018995 21.71 D 20267429 D Common Shares 2025-12-31 4 J 0 1430882 21.71 D 18836547 D Stock Option (Right to Buy) 12.68 2025-12-29 4 M 0 748358 0 D 2026-03-31 Common Shares 748358 555840 D Stock Option (Right to Buy) 12.68 2025-12-31 4 M 0 2449877 0 D 2026-03-31 Common Shares 2449877 95718 D All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.90, inclusive. These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive. Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. Award of stock options to purchase Common Shares that is fully vested. By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme 2025-12-31